LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 1 | H09 | 72 | hr | 1476 | 1388 | 3694 | 0.3757 | -0.0400 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 2 | H09 | 72 | hr | 1476 | 1387 | 3694 | 0.3755 | -0.0405 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 3 | H09 | 72 | hr | 1476 | 1435 | 3694 | 0.3885 | -0.0188 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 1 | G09 | 72 | hr | 1476 | 1020 | 3694 | 0.2761 | -0.2060 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 2 | G09 | 72 | hr | 1476 | 1305 | 3694 | 0.3533 | -0.0774 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 3 | G09 | 72 | hr | 1476 | 1406 | 3694 | 0.3806 | -0.0319 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 1 | F03 | 72 | hr | 1476 | 968 | 3694 | 0.2620 | -0.2294 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 2 | F03 | 72 | hr | 1476 | 1205 | 3694 | 0.3262 | -0.1225 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 3 | F03 | 72 | hr | 1476 | 1344 | 3694 | 0.3638 | -0.0599 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 1 | G03 | 72 | hr | 1476 | 931 | 3694 | 0.2520 | -0.2461 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 2 | G03 | 72 | hr | 1476 | 1020 | 3694 | 0.2761 | -0.2060 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 3 | G03 | 72 | hr | 1476 | 1025 | 3694 | 0.2775 | -0.2037 |
| SK-BR-3 | CHIR-99021 | 1.11 | uM | LJP6 | 1 | P15 | 72 | hr | 1476 | 3009 | 3694 | 0.8146 | 0.6911 |
| SK-BR-3 | CHIR-99021 | 1.11 | uM | LJP6 | 2 | P15 | 72 | hr | 1476 | 2925 | 3694 | 0.7918 | 0.6532 |
| SK-BR-3 | CHIR-99021 | 1.11 | uM | LJP6 | 3 | P15 | 72 | hr | 1476 | 2749 | 3694 | 0.7442 | 0.5738 |
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 1 | A09 | 72 | hr | 1476 | 1890 | 3694 | 0.5116 | 0.1864 |
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 2 | A09 | 72 | hr | 1476 | 1591 | 3694 | 0.4307 | 0.0515 |
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 3 | A09 | 72 | hr | 1476 | 1597 | 3694 | 0.4323 | 0.0542 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 1 | I09 | 72 | hr | 1476 | 3566 | 3694 | 0.9653 | 0.9423 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 2 | I09 | 72 | hr | 1476 | 3276 | 3694 | 0.8868 | 0.8115 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 3 | I09 | 72 | hr | 1476 | 2963 | 3694 | 0.8021 | 0.6703 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 1476 | 2525 | 3694 | 0.6835 | 0.4728 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 1476 | 2472 | 3694 | 0.6692 | 0.4489 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 1476 | 2390 | 3694 | 0.6470 | 0.4119 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 1 | P09 | 72 | hr | 1476 | 2711 | 3694 | 0.7339 | 0.5567 |